Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-Year follow-up in a routine clinical setting

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 961-966

  Lanari, Alessia ^a   Parnetti, Lucilla ^b  

^a Mantova General Hospital   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alzheimer's disease; CSF biomarkers; Dementia; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MEMBRANE PROTEIN; PROTEIN P TAU; TAURINE TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; DEMENTIA; DISEASE COURSE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; SPINAL PUNCTURE; TAU PROTEINS;

EID: 77649306576     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.106     Document Type: Article

References (18)

1. Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., and Kokmen, E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308.
2. Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R., Simms, G., Beyreuther, K., and Masters, C.L. (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688-1693.
3. Price, J.L. and Morris, J.C. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358-368.
4. Petersen, R.C. (2004) Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194.
5. Blennow, K. and Hampel, H. (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605-613.
6. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H.C., Riemenschneider, M., De Deyn, P.P., Bancher, C., Cras, P., Wiltfang, J., Mehta, P.D., Iqbal, K., Pottel, H., Vanmechelen, E., and Vanderstichele, H. (1999) Improved discrimination of AD patients using β-amyloid (1-42) and Tau levels in CSF. Neurology 52, 1555-1562.
7. Lewczuk, P., Kornhuber, J., Vanderstichele, H., Esselmann, H., Bibl, M., Wolf, S., Otto, M., Reulbach, U., Kölsch, H., Jessen, F., Schröder, J., Schönknecht, P., Hampel, H., Peters, O., Weimer, E., Perneczky, R., Jahn, H., Luckhaus, C., Lamla, U., Supprian, T., Maler, J.M., and Wiltfang, J. (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol. Aging 29, 812-818.
8. Zetterberg, H., Wahlund, L.O., and Blennow, K. (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 352, 67-69.
9. Hampel, H., Mitchell, A., Blennow, K., Frank, R.A., Brettschneider, S., Weller, L., and Moller, H.J. (2004) Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J. Neural Transm. 111, 247-272.
10. Parnetti, L., Lanari, A., Silvestrelli, G., Saggese, E., and Reboldi, P. (2006) Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech. Ageing Dev. 127, 129-132.
11. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., and Minthon, L. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234.
12. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E.M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 34, 939-944.
13. The Lund and Manchester Groups (1994) Clinical and neuropathological criteria for frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 57, 416-418.
14. McKeith, I.G., Perry, E.K., and Perry, R.H. (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment Consortium on Dementia with Lewy bodies. Neurology 53, 902-905.
15. Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R.C., Goetz, C.G., Golbe, L.I., Grafman, J., Growdon, J.H., Hallett, M., Jankovic, J., Quinn, N.P., Tolosa, E., and Zee, D.S. (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1-9.
16. Sjögren, M., Davidsson, P., Tullberg, M., Minthon, L., Wallin, A., Wikkelso, C., Granerus, A.K., Vanderstichele, E., and Blennow, K. (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70, 624-630.
17. Herukka, S.K., Hallikainen, M., Soinine, H., and Pirttila, T. (2005) CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294-1297.
18. Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R.G., Broe, G.A., Dickson, D., Duyckaerts, C., Cummings, J., Gauthier, S., Korczyn, A., Lees, A., Levy, R., Litvan, I., Mizuno, Y., McKeith, I.G., Olanow, C.W., Poewe, W., Sampaio, C., Tolosa, E., and Emre, M. (2007) Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22(16), 2314-2324.